Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put IMRX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 100% over the past year.
View GrowthManagement screens weak on margins.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 59% in its worst 12-month stretch.
View RiskIMRX offers exposure to its clinical program, though no material catalyst was judged in the window. Recent financial performance is weak, and the company was unprofitable over the past year. The latest recorded result was a Q2 FY2026 earnings miss, with no revenue growth figures available. No clean valuation multiple is available, so the desk cannot define a peer-multiple comparison. The price is roughly in line with the growth we forecast. Management is running behind on a stated commitment. Our model puts the next-quarter miss probability near 42%. Peer multiples imply a price about 71% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. IMRX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 7 analysts currently covering IMRX (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for IMRX in the last 4 months.
Continue this research
Compare IMRX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IMRX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put IMRX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Progress in Phase 2a clinical trial for atebimetinib
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $3.75
The last 12 months of price, then the range of analyst 12-month targets from today’s $3.75.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Positive data supports progress in clinical trial for atebimetinib.
Advances: Progress in Phase 2a clinical trial for atebimetinib
Median survival data indicates potential efficacy of atebimetinib.
Advances: Extend cash runway to fund operations into 2029
Earnings beat indicates better cash management and runway extension.